InnoSer Leadership Team

Jan has a business administration background and started his career as a professional officer in the Dutch Royal Army. This is where the foundation was laid for, among other things, team building, communication, and goal-oriented work. After 10 years of military service, he switched to business and found his passion in international work and commerce. In 2001 Jan started as general manager at Harlan in the Netherlands. In his more than 10 years at Harlan, he grew to Managing Director Northern Europe. Harlan was acquired by private equity in 2015 and Jan has gained extensive experience in branch consolidations that have led to higher customer satisfaction and profitability.

In 2013, Jan founded InnoSer and expanded it with a strong team into the customer-oriented CRO it is today with offices in Leiden and Diepenbeek, providing a global service. Due to the strong market demand for (pre)clinical pathology, Connected-Pathology BV was also established in 2021.

Kris has a PhD in Medical Sciences from Hasselt University and holds a Masters degree in chemistry from Ghent University. Kris has over 20 years of experience in the life sciences and financial sector. He started his scientific career as a Postdoctoral fellow at the Longwood Medical Research Center, Harvard Medical School and Head of oncology research at Hasselt University. Kris gained industry experience as patent and licensing manager at Johnson & Johnson and expanded his expertise in the financial sector as equity analyst and fund manager for Puilaetco Bankers.

As an independent corporate development advisor he held several advisory, management and director mandates in private and public biomedical companies including Beta-Cell, Apitope, SEPS Pharma, TiGenix, Laboratoria Smeets and Promethera.

He has also been acting as sector specialist for a number of investment boutiques and venture capital firms such as Puilaetco Bankers, Bryan Garnier, Kepler Equities, LRM and Oyster Venture Partners, where he was involved in the identification, execution and follow-up of private and public financing transactions.

Yanick Fanton graduated in 2012 with a master’s degree in clinical and molecular sciences and obtained a PhD on human cardiac stem cells for the treatment of myocardial infarction. She completed additional education in strategy, business HR and marketing via a business management post-graduate. Stem cells and cell therapy development have been a central part of both her education and her first career experiences.

Yanick joined Beta-Cell NV in 2016, a bio-tech company that is developing a cell therapy for the treatment of diabetes. She started as a scientist and switched to R&D director in 2019. As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.

After studying Business Administration and Logistics Management, Robbert started his career as a process controller in the irradiation industry. Moving to the life science industry in 2004, Robbert initially worked for Harlan Laboratories and Envigo, where he held various positions. From 2017 onwards he was Manager of Operations responsible for the European production sites of research models. In April 2021 he joined the InnoSer team as COO. His special interest lies in the field of people-oriented management, collaboration, and setting up structured and efficient work processes. His ultimate goal is to make a difference for our customers.

Maarten obtained his Master’s degree in Bioprocess Engineering at Wageningen University and a PhD degree in behavioural and molecular Neuroscience at the VU University Amsterdam. Hereafter he joined the company Sylics. As CSO, Maarten directed Sylics’ R&D team in the establishment of mouse models of CNS diseases and a suite of bioinformatics services, including cloud-based AHCODA^TM data analyses. He authored on >60 peer reviewed publications, and has a broad network in academia and pharma/biotech industry. In 2018 Maarten became the CEO of the Sylics, until its merge with InnoSer laboratories in 2023. Maarten contributes more than 15 years of experience in high quality preclinical in vivo neuroscience studies.